Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Blood (2025) 146 (Supplement 1): 372.

https://doi.org/10.1182/blood-2025-372

Published: 2025

Journal Articles

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Colin Stewart, Kevin Hay, Peter Duggan, Jan Storek, Mona Shafey, Irwindeep Sandhu, Michelle Dowhan, Robert Puckrin

Blood (2025) 146 (Supplement 1): 2761.

https://doi.org/10.1182/blood-2025-2761

Published: 2025

Journal Articles

Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience.

Alex Kwan, Irwindeep Sandhu, Peng Wang, Michael Chu, Vladimir Sapon-Cousineau

Blood (2025) 146 (Supplement 1): 2647.

https://doi.org/10.1182/blood-2025-2647

Published: 2025

Journal Articles

Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL

Jennifer Croden, Zackariah Breckenridge, Charles Yin, Carina Debes-Marun, Bindu Thapa, Irwindeep Sandhu, Michael Chu

Blood (2025) 146 (Supplement 1): 5962.

https://doi.org/10.1182/blood-2025-5962

Published: 2025

Journal Articles

Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma

Dor Abelman, David Scott, Jenna Eagles, Stephanie Pedersen, Aimée Wong, Saumil Shah, Cecilia Bonolo De Campos, Darrel White, Irwindeep Sandhu, Kevin Song, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor Pugh

Blood (2025) 146 (Supplement 1): 495.

https://doi.org/10.1182/blood-2025-495

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Adam Suleman, Kim Roos, Yidi Jiang, George Tomlinson, Kathryn Mangoff, Gail Klein, Diego Villa, David Macdonald, Mohammed Aljama, Mona Shafey, Nicholas Forward, Jean-Francois Larouche, Anna Nikonova, Michael Sebag, Irwindeep Sandhu, Rebecca McClure, Heidi Simmons, Monica Gallucci, Neil Berinstein

Blood (2025) 146 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2025-1814

Published: 2025

Journal Articles

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Simon Harrison, Caroline Hasselbalch Riley, Hira Mian, Andrew Spencer, Noa Lavi, Laura Paris, Jana Mihalyova, Rakesh Popat, Monika Szarejko, Sebastian Grosicki, Kihyun Kim, Irwindeep Sandhu, Sammy Chebon, Tulika Tyagi, Paresh Sewpaul, Leanne Richardson, Kerstin Trunzer, Ameet Mishra, Suzanne Trudel

Blood (2025) 146 (Supplement 1): 252.

https://doi.org/10.1182/blood-2025-252

Published: 2025

Journal Articles

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Blood (2025) 145 (15): 1658–1669.

https://doi.org/10.1182/blood.2024025897

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Vania Hungria, Marek Hus, Pawel Robak, Vera Zherebtsova, Ana Carolina de Almeida Ribas, Marcelo Pitombeira de Lacerda, Kihyun Kim, Sebastian Grosicki, Irwindeep Sandhu, Christopher Ward, Astrid McKeown, Hena Baig, Jie Ma, Benjamin Lariviere, Benga Kazeem, Lydia Eccersley, Sumita Roy-Ghanta, Joanna Opalinska, Maria Victoria Mateos

Blood (2024) 144 (Supplement 1): 3359.

https://doi.org/10.1182/blood-2024-201543

Published: 2024

Journal Articles

Gene Expression Profile of Enriched T-Cells Prior to Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Is Predictive of CAR T-Cell Response

Bee S Tan, Charles Yin, Pankajkumar Tailor, Bindu Thapa, Carina Debes-Marun, Deanna Hockley, Irwindeep Sandhu, Michael P. Chu

Blood (2024) 144 (Supplement 1): 4366.

https://doi.org/10.1182/blood-2024-212330

Published: 2024

Journal Articles

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Donna E Reece, Giovanni Piza Rodriguez, Mariela A Pantoja, Eshetu G Atenafu, Darrell White, Irwindeep Sandhu, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger E Tiedemann, Christine I Chen

Blood (2024) 144 (Supplement 1): 3376.

https://doi.org/10.1182/blood-2024-206247

Published: 2024

Journal Articles

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Dor D. Abelman, Jenna Eagles, Aimee Wong, Saumil Shah, Stephanie Pedersen, Sarah Bridges, Cecilia Bonolo De Campos, Darrell White, Irwindeep Sandhu, Kevin Song, Zac McDonald, Abir Khaled, Liqiang Yang, Alli Murugesan, Anthony Reiman, Suzanne Trudel, Trevor J. Pugh

Blood (2024) 144 (Supplement 1): 3338.

https://doi.org/10.1182/blood-2024-208740

Published: 2024

Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Blood (2024) 144 (Supplement 1): 1025.

https://doi.org/10.1182/blood-2024-198408

Published: 2024

Journal Articles

Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Michael P. Chu, Zack Breckenridge, Deanna Hockley, Mona Shafey, Sunil J. Desai, Victor A. Lewis, Peng Wang, Vladimir Sapon-Cousineau, Charles Yin, Carina Debes-Marun, Irwindeep Sandhu

Blood (2024) 144 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2024-209646

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Victor H. Jimenez-Zepeda, Irwindeep Sandhu, Michael P. Chu, Kathryn Rankin, Arleigh McCurdy, Hyra Sapru, Christopher Cipkar, Edward Koo, Benjamin Patrick, Sarah Albert, Meriem Henia, Christopher McCudden, Alissa Visram

Blood (2024) 144 (Supplement 1): 1912.

https://doi.org/10.1182/blood-2024-209251

Published: 2024

Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein

Blood (2024) 144 (Supplement 1): 6291.

https://doi.org/10.1182/blood-2024-203317

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Blood (2024) 144 (Supplement 1): 772.

https://doi.org/10.1182/blood-2024-200336

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Daratumumab monotherapy versus active monitoring in patients with high-risk smoldering multiple myeloma: Aquila outcomes based on mayo 2018/IMWG 2020 risk stratification, IMWG 2020 plus cytogenetic criteria, and age

Outcomes of autologous stem cell transplantation using busulfan-melphalan conditioning with pharmacokinetic monitoring for relapsed diffuse large B-cell lymphoma

Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience.

Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL

Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Efficacy and tolerability of bendamustine, rituximab and acalabutinib in elderly treatment naïve Waldenström's macroglobulinemia

Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: Biomarker analyses from CAMMA 1 Arm B

Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

Efficacy Outcomes By Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated with Belantamab Mafodotin Plus Bortezomib and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone: Analysis from the Dreamm-7 Trial

Gene Expression Profile of Enriched T-Cells Prior to Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Is Predictive of CAR T-Cell Response

Final Results of the Canadian Myeloma Research Group Trial of Cybord Induction, Double-Alkylator Conditioning with High-Dose Intravenous Busulfan + Melphalan, ASCT and Continuous Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma (CMRG-001)

Cell-Free DNA Whole Genome Sequencing for Non-Invasive MRD Detection in Multiple Myeloma

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only